A Phase 2 Open Label Trial of ST266 Eye Drops in the Treatment of Persistent Corneal Epithelial Defects
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs ST 266 (Primary)
- Indications Corneal disorders
- Focus Therapeutic Use
- Sponsors Noveome
- 15 Aug 2019 Planned End Date changed from 1 Apr 2020 to 1 Jun 2020.
- 15 Aug 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Jan 2020.
- 13 Jun 2019 According to a Noveome media release, top-line data from this study is expected by end of 2019.